7,000,000 Shares GlycoMimetics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 21st, 2018 • Glycomimetics Inc • Pharmaceutical preparations • New York
GLYCOMIMETICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt SecuritiesIndenture • March 4th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
AND [__________], As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of GlycoMimetics, Inc. Form of Preferred Stock Warrant AgreementWarrant Agreement • March 4th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [•], between GlycoMimetics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
GLYCOMIMETICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OFCommon Stock Warrant Agreement • May 17th, 2019 • Glycomimetics Inc • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between GLYCOMIMETICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
GlycoMimetics, Inc. AND [_____________], As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of [__________] GlycoMimetics, Inc. Form of Debt Securities Warrant AgreementWarrant Agreement • March 4th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
This Debt Securities Warrant Agreement (this “Agreement”), dated as of [•], between GlycoMimetics, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
GLYCOMIMETICS, INC. Common Stock (par value $0.001 per share) SALES AGREEMENTSales Agreement • April 28th, 2022 • Glycomimetics Inc • Pharmaceutical preparations • New York
GlycoMimetics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
GLYCOMIMETICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFPreferred Stock Warrant Agreement • May 17th, 2019 • Glycomimetics Inc • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between GLYCOMIMETICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
GLYCOMIMETICS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFDebt Securities Warrant Agreement • March 17th, 2015 • Glycomimetics Inc • Pharmaceutical preparations • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between GLYCOMIMETICS, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
GLYCOMIMETICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFSecurities Warrant Agreement • May 17th, 2019 • Glycomimetics Inc • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between GLYCOMIMETICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
ContractGlycomimetics Inc • October 4th, 2013 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.
LEASE by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company and GLYCOMIMETICS, INC., a Delaware corporationLease • July 28th, 2014 • Glycomimetics Inc • Pharmaceutical preparations
THIS LEASE (this “Lease”) is entered into as of this 23rd day of July, 2014 (the “Execution Date”), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (“Landlord”), and GLYCOMIMETICS, INC., a Delaware corporation (“Tenant”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 3rd, 2023 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
This Executive Employment Agreement (the “Agreement”) is entered into effective February 10, 2023 (the “Effective Date”), by and between Chinmaya Rath and GlycoMimetics, Inc. (the “Company”).
GLYCOMIMETICS, INC. Common Stock Purchase WarrantGlycomimetics Inc • October 4th, 2013 • Pharmaceutical preparations • Delaware
GLYCOMIMETICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • October 28th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
This INDEMNIFICATION AGREEMENT, dated and effective as of (this “Agreement”), is by and between GLYCOMIMETICS, INC., a Delaware corporation (the “Company” (as such definition is further expanded below)), , and, if such individual is a Director serving the Company as a representative of an entity, (each an “Indemnitee” and collectively, the “Indemnitees”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2014 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 15, 2014 (the “Effective Date”), by and between Rachel K. King (“Executive”) and GLYCOMIMETICS, INC. (the “Company”).
GLYCOMIMETICS, INC. Common Stock (par value $0.001 per share) SALES AGREEMENTSales Agreement • October 7th, 2020 • Glycomimetics Inc • Pharmaceutical preparations • New York
GlycoMimetics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
LICENSE AGREEMENTConfidential Treatment • October 31st, 2013 • Glycomimetics Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT dated as of the 7th day of October, 2011 (the “Agreement”) is made between GlycoMimetics, Inc., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (“GMI”) and Pfizer Inc., a Delaware corporation having its principal place of business at 235 East 42nd Street, New York, New York 10017 (“Pfizer”).
SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of the 20th day of October, 2009 by and among GlycoMimetics, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit 1.01, as updated from time to time, hereto (the “Investors”) and each Person who shall, after the date hereof, acquire shares of Series A-1 Preferred Stock of the Company pursuant to (A) the Purchase Agreement (as defined below) or (B) a transfer of shares of Restricted Stock (as defined below) wherein rights under this Agreement are validly assigned, and joins in and becomes a party to this Agreement by executing and delivering to the Company a counterpart signature page in the form attached hereto and who shall be listed on an updated Exhibit 1.01, each of which is also herein referred to as an “Investor” and collectively as the “Investors.”
GLYCOMIMETICS, INC2003 Stock Incentive Plan • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
GlycoMimetics, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, $.001 par value, (the “Stock”) to the optionee named below. The terms and conditions of the option are set forth in this cover sheet, in the attachment and in the Company’s 2003 Stock Incentive Plan (the “Plan”).
GLYCOMIMETICS, INC.Stock Incentive Plan • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations • Delaware
GlycoMimetics, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, $.001 par value, (the “Stock”) to the optionee named below. The terms and conditions of the option are set forth in this cover sheet, in the attachment and in the Company’s 2003 Stock Incentive Plan (the “Plan”).
LEASE AGREEMENTLease Agreement • October 4th, 2013 • Glycomimetics Inc • Pharmaceutical preparations
THIS LEASE AGREEMENT (“this Lease”) is made as of this 1st day of July, 2010, between ARE-QRS CORP., a Maryland corporation (“Landlord”), and GLYCOMIMETICS, INC., a Delaware corporation (“Tenant”).
Exhibit A CONSULTING AGREEMENTConsulting Agreement • November 13th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
THIS CONSULTING AGREEMENT (the “Agreement”) by and between GlycoMimetics, Inc. (“Client”) and Edwin Rock an individual (“Consultant”) is effective as of July 31, 2024 (the “Effective Date”), subject to the terms of Section 14 below.
ContractProject Agreement • March 27th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions.
July 30, 2024 Edwin Rock Via Email Re:Separation Agreement Dear Ed:Glycomimetics Inc • November 13th, 2024 • Pharmaceutical preparations
This letter sets forth the substance of the separation agreement (the “Agreement”) which GlycoMimetics, Inc. (the “Company”) is offering to you to aid in your employment transition.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2014 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of May 19, 2003, is by and between, GLYCOMIMETICS, INC., a Delaware corporation (the “Company”) and John Magnani, Ph.D. (the “Executive”).
SECOND AMENDMENT TO LEASELease • March 27th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 20 day of April, 2018 (“Second Amendment Execution Date”), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (“Landlord), and GLYCOMIMETICS, INC., a Delaware corporation (“Tenant”).
Execution Version August 7, 2024 Brian Hahn RE:RETENTION AGREEMENT AND OFFER OF REVISED SEVERANCE ELIGIBILITY Dear Brian:Employment Agreement • November 13th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
Thank you for all of your contributions to GlycoMimetics, Inc. (the “Company”). Your role is critical to the next phase of the Company. Our hope is that, despite the fact that you may have other employment opportunities, you will remain employed with the Company until the Company concludes that your position is no longer required. To financially incentivize you to remain employed by the Company for this period (which we expect may be several months), we are pleased to offer you a retention bonus and enhanced severance eligibility, as summarized below.
COLLABORATION AND LICENSE AGREEMENT1Collaboration and License • February 28th, 2020 • Glycomimetics Inc • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of January 2, 2020 (the “Effective Date”) by and between GLYCOMIMETICS, INC., a corporation organized and existing under the laws of Delaware and having a place of business at 9708 Medical Center Drive, Rockville, MD 20850 (“GlycoMimetics”), and APOLLOMICS (HONG KONG), LIMITED, a Hong Kong entity along with its Affiliates having one of its places of business at 989 East Hillsdale Blvd. Suite 220, Foster City, CA 94404 (“Apollomics”). GlycoMimetics and Apollomics are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Execution Version August 7, 2024 Harout Semerjian RE:RETENTION AGREEMENT AND OFFER OF REVISED SEVERANCE ELIGIBILITY Dear Harout:Employment Agreement • November 13th, 2024 • Glycomimetics Inc • Pharmaceutical preparations
Thank you for all of your contributions to GlycoMimetics, Inc. (the “Company”). Your role is critical to the next phase of the Company. Our hope is that, despite the fact that you may have other employment opportunities, you will remain employed with the Company until the Company concludes that your position is no longer required. To financially incentivize you to remain employed by the Company for this period (which we expect may be several months), we are pleased to offer you a retention bonus and enhanced severance eligibility, as summarized below.
Re:Transition Agreement Dear John: This letter sets forth the substance of the Transition Agreement (the “Transition Agreement” or “Agreement”) which GlycoMimetics, Inc. (the “Company”) is offering to you.Transition Agreement • May 3rd, 2023 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
Consulting AgreementConsulting Agreement • May 3rd, 2023 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
This Consulting Agreement (the “Agreement”) by and between GlycoMimetics, Inc. (“Client”) and John Magnani, Ph.D., an individual (“Consultant”) is effective as of March 31, 2023 (the “Effective Date”).
FIRST AMENDMENT TO LEASELease • March 29th, 2016 • Glycomimetics Inc • Pharmaceutical preparations
to us on or before the Expiry Date, provided we also receive (on or before the Expiry Date) any other Drawing Documentation this L/C requires.
CONSULTING AGREEMENTConsulting Agreement • March 3rd, 2022 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
THIS CONSULTING AGREEMENT (the “Agreement”) by and between GlycoMimetics, Inc. (“Client”) and Rachel K. King, an individual (“Consultant”) is effective as of August 31, 2021 (the “Effective Date”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 2nd, 2019 • Glycomimetics Inc • Pharmaceutical preparations • Maryland
This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective March 1, 2019 (the “Effective Date”), by and between Armand Girard (“Executive”) and GlycoMimetics, Inc. (the “Company”).
Release AgreementRelease Agreement • May 3rd, 2023 • Glycomimetics Inc • Pharmaceutical preparations
This Release Agreement (“Release”) is made by and between GlycoMimetics, Inc. (the “Company”) and Armand Girard (“you”). You and the Company entered into an Amended and Restated Employment Agreement dated July 30, 2019 (the “Employment Agreement”). You and the Company hereby further agree as follows:
